Valbiotis Announces the Completion of Recruitment for the Phase II HEART Clinical Study Conducted With TOTUM•070 in Hypercholesterolemia, a Risk Factor for Cardiovascular Disease
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a French research and development company committed to scientific innovation for preventing and combating metabolic diseases, announces that it has completed the recruitment of 120 volunteers for the Phase II HEART clinical study at the beginning of September 2021, in accordance with the schedule announced by the Company. In line with its development plan, Valbiotis confirms that the results of the HEART study will be available in the second quarter of 2022.
The HEART clinical study is a multicenter, international, randomized, placebo-controlled, double-blind study involving 120 people with untreated moderate hypercholesterolemia between 130 and 190 mg/dL. Participants are divided into two equivalent arms of 60 people, supplemented for 6 months with TOTUM•070 or placebo. The primary endpoint of the HEART study is the reduction of blood LDL-cholesterol levels, a risk factor for cardiovascular disease and in particular atherosclerosis, and it has several secondary objectives of interest.
Murielle CAZAUBIEL, Head of Development, Medical, Regulatory and Industrial Affairs, member of the Valbiotis Board of Directors, comments: "We are completing enrollment in the HEART clinical study and we are delighted with the progress of this study and look forward to seeing the results in a few months. The medical need is real: according to the WHO, nearly 40% of the world's adult population has high cholesterol, a well-known cardiovascular risk factor. High-risk patients are generally treated with drug-based approaches. But for more moderate forms, there is a lack of a non-drug, open-label, clinically proven option to reduce excess blood LDL-cholesterol before it becomes too high risk. We are developing TOTUM•070 to bring this preventive option to as many people as possible."
TOTUM•070 is an innovative active substance derived from food plant extracts, without phytosterols or red yeast rice, developed to act on lipid metabolism in people with hypercholesterolemia. Once development is completed, TOTUM•070 will be indicated for people with LDL-hypercholesterolemia, for levels up to 190 mg/dL, with a moderate overall cardiovascular risk. TOTUM•070 could be recommended in this large population for whom no first-line drug treatment is currently recommended (see press release of October 27, 2020).
Sébastien BESSY, Head of Marketing and Commercial Operations, member of the Valbiotis Board of Directors, states: "The HEART clinical study is a key element in the marketing strategy: it is designed to demonstrate the efficacy of our active substance TOTUM•070 for people at risk who are not currently receiving treatment. The market for untreated hypercholesterolemia is already very significant and is worth 1.2 billion euros in Europe and the United States2. In these vast markets, the success of HEART would give TOTUM•070 a decisive advantage with consumers."
Untreated hypercholesterolemia: the large market of non-drug products
In the 5 major European countries (France, Germany, Italy, Spain, United Kingdom) and the United States, an estimated 174 million adults have elevated LDL-cholesterol levels2,3. Thanks to a high diagnosis rate, approaching 50%, the diagnosed population is 83 million people2.
However, in accordance with the recommendations, only people at high overall cardiovascular risk are treated. A large proportion of those diagnosed are therefore already turning to non-drug products, notably in the USA (54% of people diagnosed), the UK (58%), France (34%) and Germany (35%)2. The market for these LDL-cholesterol lowering products is today estimated at nearly €1.2 billion in these regions, including more than €600 million in the United States2.
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com.
ISIN code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document approved by the French Financial Markets Regulator (AMF) on July 27, 2021 (application number R 21-039). This document is available on the Company’s website (www.valbiotis.com).
This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.
12018 Guideline on the Management of Blood Cholesterol, a report from the American College of Cardiology / American Heart Association, Journal Of The American College Of Cardiology, 2019.
2AEC Partners data, 2019, for Valbiotis.
3Blood LDL-cholesterol level greater than 100 or 130 mg/dL, depending on available data.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Corporate communication / Valbiotis
Carole Rocher / Marc Delaunay
+33 5 46 28 62 58
Financial communication / Actifin
+33 1 56 88 11 14
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
‘Hidden Gem’ Arrives in Rotterdam to be Transformed into Nodule Collection Vessel for The Metals Company21.9.2021 18:37:00 CEST | Press release
The Metals Company (Nasdaq: TMC) today announced that the 228-meter-long former drill ship renamed the Hidden Gem has arrived in Rotterdam, The Netherlands to begin its conversion into what is expected to be the first ship classified as a sub-sea mining vessel by the American Bureau of Shipping. TMC’s strategic partner Allseas acquired the former ultra-deep-water drill ship, which can accommodate 200 people, in March of 2020, as her configuration is well-suited for modifications that will enable the deployment at sea of a 4.5 kilometer-long riser to bring polymetallic nodules up from the seafloor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005945/en/ Hidden Gem vessel (Photo: Business Wire) In partnership with The Metals Company (formerly DeepGreen Metals Inc.), Allseas is developing a deep-sea mineral collection system to responsibly recover polymetallic nodules from the ocean floor and transfer them to the surfac
Rhizen Pharmaceuticals AG Announces First Patient Dosed in a Phase 2 Study of RP7214 in Covid-19 Patients21.9.2021 18:36:00 CEST | Press release
Rhizen Pharmaceuticals AG, a clinical-stage oncology & inflammation-focussed biopharmaceutical company, today announced that the first patient has been dosed in a Phase 2 clinical trial of RP7214, a small molecule oral dihydroorotate dehydrogenase (DHODH) Inhibitor. The randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy & safety of oral RP7214, in covid-19 patients with mild, symptomatic disease with an underlying risk factor on the background of promising preclinical efficacy & phase 1 healthy volunteer safety. The study is being conducted in India across 12 centres in coordination with Rhizen’s India affiliate, Incozen Therapeutics Pvt ltd., and is designed to enrol up to 204 patients across both study arms. Viral replication involves a huge demand for building blocks and relies on nucleotides derived from host cells. DHODH is a rate-limiting enzyme in the pyrimidine biosynthesis pathway, inhibition of which leads to depletion of host nucleotide po
Citi Private Bank Finds Cautious Optimism Among Investors for 2022 with Covid-19, Inflation and Peak Market Valuations Top of Mind21.9.2021 18:31:00 CEST | Press release
Citi Private Bank’s Private Capital Group today released the results of its 2021 Family Office Survey, compiling the unique perspectives and insights of many of the world’s sophisticated family offices and ultra-high net worth investors in a challenging climate. This year’s survey included nearly 200 responses, an 11% increase from 2020. Four predominant themes emerged: 1) concern on rising inflation, 2) the prominence of high cash levels in the face of low yield environment, 3) continued growth in portfolio allocation to direct investing opportunities, and 4) a marked comeback in portfolio values year over year despite prevalent degree of macroeconomic uncertainty. While over three-fourths of all respondents seek returns of 5% or more over the next 12 months, the outlook is more optimistic for family offices with AUM over $500 million with 30% seeking over 10% returns versus 19% of family offices with AUM under $500 million. This likely factors in the additional institutional tools an
SSIMWAVE Selects Verimatrix Code Protection to Prevent Reverse Engineering of its Award-Winning Video Experience Platform21.9.2021 17:45:00 CEST | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Ontario, Canada-based SSIMWAVE Inc. is one of its latest customers to integrate Verimatrix Code Protection technology. IP theft is a growing threat to organizations worldwide. The Commission on the Theft of American Intellectual Property estimates that costs from IP losses are as high as $600 billion annually. “Verimatrix has a lengthy and successful history in the media and entertainment space, so it made sense to turn to their code protection technologies,” said Peter Olijnyk, Vice President of Engineering at SSIMWAVE. “When you’re protecting the core foundation of your platform, Verimatrix’s transparent and timely process for getting up and running – not to mention in about a day or so – was reassuring and provides peace of mind for SSIMWAVE and our customers.” A video quality innovator, SSIMWAVE evaluated numerous vendors and deci
Latest Report From Arthur D. Little Brings New Perspectives on Mobility-as-a-Service (MaaS)21.9.2021 17:22:00 CEST | Press release
Arthur D. Little (ADL) today released a new report on the current state of the global Mobility-as-a-Service (MaaS) market. Entitled ‘How To Realize The Promise Of Mobility-as-a-Service’, this study is released by the company’s Future Of Mobility Lab. While much has been written over the past few years about MaaS and its vision of revolutionizing transport in the modern city, much of the current discourse has been either academic or conceptual, envisaging ambitious futures built on fragile foundations. With this study, ADL aims to offer a more objective view of the subject, based on the company’s wide-ranging consultation with both public and private actors, and its assessment of the successes and failures of real world MaaS deployments. The study identifies five key factors for achieving a successful MaaS deployment. These are: Recognizing that MaaS is more than just an app, but should be part of a broader mobility vision requiring the development of integrated mobility policies, physi
project44 Buys Last-Mile Delivery and Customer Experience Leader, Convey, in $255M Acquisition21.9.2021 16:00:00 CEST | Press release
project44, the global leader in real-time supply chain visibility, today announced that it has acquired Austin-based Convey, the last-mile technology leader that powers exceptional direct-to-consumer delivery experiences for more than 200 of the world’s largest brands, including The Home Depot, Nieman Marcus, Ferguson, Ingram-Micro, and others. Convey, recognized as a Challenger in the Gartner 2021 Magic Quadrant for Real-Time Visibility Platforms, combines real-time visibility, post-purchase experiences, and machine learning-powered analytics to improve the overall customer experience. Together, the two companies now serve the global supply chain end-to-end, providing real-time visibility and actionable insights from raw materials to the front door to help brands deliver differentiated direct-to-consumer and eCommerce experiences for their customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005205/en/ project44
Andersen Global Continues Asian Expansion With Malaysian-Based Law Firm21.9.2021 15:30:00 CEST | Press release
Andersen Global continues its expansion in Asia through a Collaboration Agreement with Malaysian-based law firm Halim Hong & Quek Advocates & Solicitors (HHQ). Founded in 2000, HHQ offers full-service legal capabilities in alternative dispute resolution, banking and finance, corporate and M&A, energy and infrastructure, litigation, real estate and construction. With offices in Kuala Lumpur, Johor and Penang, the firm provides services to a wide range of domestic and international companies as well as high net worth individuals and foreign investors. “Our goal is to empower individuals and businesses with best-in-class legal services while creating a value-added social impact through our capabilities,” Managing Partner Dato’ Quek Ngee Meng. “We hire those who strive for the best and possess a positive mindset. Our team is dedicated to investing in our people to bring exceptional service and solutions to our clients. Collaborating with Andersen Global expands our platform and ability to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom